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Abstract Drainage of central nervous system (CNS) anti-
gens to the brain-draining cervical lymph nodes (CLN) is
likely crucial in the initiation and control of autoimmune
responses during multiple sclerosis (MS). We demonstrate
neuronal antigens within CLN of MS patients. In monkeys
and mice with experimental autoimmune encephalomyelitis
(EAE) and in mouse models with non-inflammatory CNS
damage, the type and extent of CNS damage was associated
with the frequencies of CNS antigens within the cervical
lymph nodes. In addition, CNS antigens drained to the
spinal-cord-draining lumbar lymph nodes. In human MS
CLN, neuronal antigens were present in pro-inflammatory
antigen-presenting cells (APC), whereas the majority of
myelin-containing cells were anti-inflammatory. This may
reflect a different origin of the cells or different drainage
mechanisms. Indeed, neuronal antigen-containing cells in
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human CLN did not express the lymph node homing
receptor CCR7, whereas myelin antigen-containing cells in
situ and in vitro did. Nevertheless, CLN from EAE-affected
CCR7-deficient mice contained equal amounts of myelin
and neuronal antigens as wild-type mice. We conclude that
the type and frequencies of CNS antigens within the CLN
are determined by the type and extent of CNS damage.
Furthermore, the presence of myelin and neuronal antigens
in functionally distinct APC populations within MS CLN
suggests that differential immune responses can be evoked.
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APC antigen-presenting cell
CFA complete Freund’s adjuvant
CLN cervical lymph node
CNS central nervous system
CSF cerebrospinal fluid
EAE experimental autoimmune encephalomyelitis
ECL entorhinal cortex lesion
FNA facial nerve axotomy
IL-1ra IL-1 receptor antagonist
LLN lumbar lymph nodes
MAP-2 microtubule-associated protein-2
MCAO middle cerebral artery occlusion
MHC major histocompatibility complex






Irreversible neuronal damage is a major pathological feature
of multiple sclerosis (MS) and ranges from mild pathology
to complete axonal transection [1, 2]. The cause of neuronal
damage is not yet elucidated, but autoreactive B and T cells
directed against neuronal antigens could conceivably be
instrumental [3]. Indeed, MS patients have increased
circulating antibody levels against the neuronal proteins
neurofilament light (NF-L) and neurofilament heavy (NF-H)
[4–6] in serum and against the medium subunit of neuro-
filament in cerebrospinal fluid (CSF) [7]. In addition, T
cells from MS patients proliferate in response to the
neuronal antigens synapsin and neuron-specific enolase
(NSE) [8, 9]. In mice, T-cell-mediated autoimmunity
against neuronal antigens leads to central nervous system
(CNS) inflammation and experimental autoimmune en-
cephalomyelitis (EAE) symptoms [10–14].
Autoreactive lymphocytes against myelin proteins and
likely also against neuronal antigens are recruited into the
CNS [2]. Where in the body these lymphocytes initially are
activated is still unclear. This is a critical issue, in view of
possible therapeutic interventions aiming to limit activation
of autoreactive T cells. Under experimental conditions,
dendritic cells activate naïve CD4+ transgenic T cells
directed against proteolipid protein (PLP)139-151 within the
CNS [15]. However, the classical view on the initiation of
naïve T cell activation holds that antigens or antigen-
containing antigen-presenting cells (APC) must be trans-
ferred to the brain-draining cervical lymph nodes (CLN) to
effectively activate naïve T cells [16, 17]. CNS-resident
APC subsequently reactivate these antigen-experienced T
cells and allow them to exert their effector functions within
the target organ [18, 19]. A crucial role of the CLN in CNS
inflammation is supported by the observation that surgical
removal of the CLN reduced the number of brain lesions in
cryolesion-enhanced EAE in the rat [20]. Furthermore,
myelin basic protein, PLP, and neutral lipid-containing
APC are present in the CLN of MS patients and EAE-
affected marmoset and rhesus monkeys [21, 22]. These
APC stimulated myelin-specific T cell proliferation [21],
demonstrating that myelin drainage to the CLN during
demyelinating disease results in the activation of autor-
eactive T cells.
We hypothesize that drainage of neuronal antigens from
the target organ to the CLN may be similarly involved in
initiating or modulating neuron-specific immune responses.
We have analyzed whether brain-derived neuronal antigens
are present in CLN of MS patients and of selected animal
models with different degrees of CNS damage. In addition,
we determined whether these antigens are present in distinct
APC subsets, which may influence T cell activation.
Materials and methods
MS tissues
Human jugular (deep) CLN and supraclavicular CLN were
taken from MS patients with active disease at autopsy.
Chronic inactive and active plaques were present in the
cerebrum of these patients. The MS patients died of non-MS-
related causes. In addition, CLN were taken from controls
without neurological disease at autopsy by the Netherlands
Brain Bank (coordinator Dr. R. Ravid). CLN were snap-
frozen in liquid nitrogen and stored at −80°C until use.
EAE tissues
All animal studies in the current study followed the
principles of animal care and were approved by local
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ethical committees based on national legislation. Tissues
were obtained from animals that were used for studies
designed for other purposes, thus avoiding the sacrifice of
animals for the present study only.
Deep CLN were isolated from rhesus monkeys (Macaca
mulatta) with acute EAE (n=5) which was induced as
described [23] and from rhesus monkeys with collagen-
induced arthritis (n=3) [24]. Deep CLN were also isolated
from common marmoset monkeys (Callithrix jacchus)
during chronic EAE (n=5) [25, 26]. Control CLN were
from marmosets (n=2) immunized with ovalbumin in
complete Freund’s adjuvant (CFA) [21]. The monkeys were
housed at the Biomedical Primate Research Center (BPRC,
Rijswijk, the Netherlands).
Deep and superficial CLN were isolated from Biozzi
ABH (H-2dq1) mice, obtained from stock bred at the BPRC,
at the acute phase of disease (n=3) and during the first
relapse (n=3). EAE was induced by immunization with
spinal cord homogenate or myelin oligodendrocyte glyco-
protein (MOG)8-21 in CFA as described [27, 28]. Deep and
superficial CLN were also isolated from CCR7-deficient
(n=4) and wild-type mice (n=4) [29] with chronic EAE,
obtained from stock bred at the animal facility of the Max
Delbrück Center for Molecular Medicine (Berlin, Germany).
Chronic EAE was induced by s.c. injections of 200 μg
MOG35-55 emulsified in CFA (Difco Laboratories) contain-
ing 400 μg of Mycobacterium tuberculosis. Mice received
i.v. injections with 200 ng Bordetella pertussis toxin (Sigma)
on days 0 and 2 postimmunization. The CCR7-deficient
mice used in these experiments had been backcrossed to
C57BL/6 mice for eight generations.
All animals were examined daily for clinical symptoms
of EAE as described [21, 25, 28, 30]. Tissues were snap-
frozen in liquid nitrogen and stored at −80°C.
Non-inflammatory CNS damage models
Ischemia was induced in C57BL/6 mice (BgVV) by
occlusion of the left middle cerebral artery (MCAO) [31].
The MCAO did not exceed 60 min. CLN were isolated 24 h
(n=5) and 72 h (n=5) after MCAO. Entorhinal cortex lesion
(ECL) and facial nerve axotomy (FNA) were performed as
described [32] in C57BL/6 mice (n=5 and n=3, respectively;
Charles River). CLN were isolated 7 days later.
Demyelination was induced chemically by cuprizone
(Sigma-Aldrich) in SJL/J mice (n=3; Janvier) and C57BL/6
mice (n=3; Harlan) as described [33]. These animals were
representative animals within a larger experiment designed
for other purposes, consisting of 18 SJL/J mice and 18
C57BL/6 mice. Five to 6 weeks after start of treatment with
cuprizone, superficial CLN, deep CLN, and lumbar lymph
nodes (LLN) were isolated. All tissues were snap-frozen
and stored at −80°C.
Immunohistochemistry
Immunohistochemistry was performed as described [34,
35]. Primary antibodies were polyclonal rabbit antibodies
against transcription growth factor (TGF)-β (Santa Cruz)
and NF-L (Abcam), and monoclonal mouse antibodies
against NSE (MIG M3; Abcam), microtubule-associated
protein-2 (MAP-2; HSM 5; Pierce Biotechnology), NF-H
(SMI-32; Sternberger Monoclonals), PLP (J1/06 [36]),
HLA-DP/DQ/DR (CR3/43; DAKO), CD40 (5D12; dr. M.
de Boer), interleukin 1 receptor antagonist (IL-1ra;
A71B6D11; Bioscource), tumor necrosis factor (TNF)-α
(61E71; U Cytech), IL-12p40/p70 (C8.6; BD), and CCR7
(2H4; BD).
Primary antibodies were detected by biotinylated donkey
anti-rabbit immunoglobulin (Ig; Amersham) or rabbit anti-
mouse Ig (DAKO) and horseradish peroxidase (HRP)-
conjugated avidin–biotin complex (DAKO). HRP activity
was revealed with 3-amino-9-ethylcarbazole (Sigma-
Aldrich), which resulted in a red precipitate. Brain or
spinal cord sections from the same species were used as
positive control tissue. As negative controls, sections were
incubated with isotype-matched primary antibodies of
irrelevant specificity, or the primary antibody was omitted.
Immunofluorescence
Double labeling was performed using immunofluorescence
as described [37]. Sections were incubated with primary
antibodies for 1 h at room temperature (RT), followed by
fluorescein isothiocyanate (FITC)- or tetramethylrhodamine
isothiocyanate (TRITC)-labeled rabbit anti-mouse Ig
(DAKO) or TRITC-labeled swine anti-rabbit Ig (DAKO)
for 30 min at RT. Subsequently, sections were incubated for
1 h at RT with Alexa594-labeled anti-MAP-2 (IgG1 Zenon
labeling kit, Molecular Probes) or with anti-MOG for 1 h at
RT, followed by biotinylated anti-IgG2a (SBA) for 30 min
at RT and FITC-labeled streptavidin (DAKO) for 1 h at RT.
Sections were mounted in glycerol–Tris–4’,6-diamidino-2-
phenylindole (DAPI; 50 μg/ml; Molecular Probes).
As controls, single stainings were performed following
the procedure described above but with omission of one of
the primary antibodies used in the double staining. Human
reactive tonsil or brain was used as positive control tissue.
Negative controls are described above.
CCR7 expression by myelin-laden human
monocyte-derived macrophages
Monocytes from healthy donors were routinely purified and
cultured [38]. For the current study, experiments were
performed with cells from two individual donors that
responded representatively for at least 50 donors assessed
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in the preceding years. Monocyte-derived macrophages
were seeded into 24-well tissue culture plates at 2×105 cells
per well. After 24 h, non-adherent cells were removed and
the remaining cells were incubated with human myelin [39]
for the indicated times. Control macrophages were obtained
from the same donor.
Total mRNA was extracted from cell cultures as
described [38]. CCR7 mRNA expression was analyzed by
real-time polymerase chain reaction using the iCycler (Bio-
rad) and the iQ SYBR Green supermix (Bio-rad). The
housekeeping gene HPRT1 was used for normalization.
The following primers were used: 5′-TGGTCGTGGTCTT
CATAGTC-3′ and 5′-CAGGTGCTACTGGTGATGTT-3′ for
CCR7 and 5′-TGACACTGGCAAAACAATGCA-3′ and 5′-
AGCTTGCTGGTGAAAAGGACC-3′ for HPRT1.
CCR7 surface expression by human monocyte-derived
macrophages was determined using flow cytometry. Fc
receptors were blocked using 20% Fc-block (Miltenyi
Biotec) and CCR7 was stained using phycoerythrin-labeled
mouse anti-CCR7 (150503; R&D Systems) for 30 min on
ice. An isotype-matched antibody of irrelevant specificity
was used as negative control. Samples were analyzed on a
FACSCalibur flow cytometer using CellQuest analysis
software (Becton Dickinson).
T cell proliferation assay
Deep CLN, superficial CLN, and LLN were isolated from
C57BL/6 mice with chronic EAE and from Biozzi ABH
mice with relapsing–remitting EAE. EAE in C57BL/6 mice
was induced by immunization with 200 μg MOG35-55 in
CFA [30] and in Biozzi ABH mice as described above.
Lymph nodes from five to ten EAE-affected animals were
pooled per experiment to obtain enough cells for restimu-
lation. A single cell suspension was obtained by passing the
lymph nodes through a 70-μm gauze. Lymph node cells,
2×105, were seeded into 96-well round-bottomed plates
(Nunc) and stimulated with the indicated concentrations of
MOG8-21, MOG35-55 (both from Advanced Biotechnology
Center, Imperial College London), recombinant mouse NF-
L (rmNF-L) [40], or ovalbumin (Worthington). After 4 days,
T cell proliferation was determined by incorporation of
[3H]-thymidine for 18 h (Amersham Biosciences) as
described [30].
Image analysis
The area of the sections was measured using a VIDAS-RT
image analysis system (Kontron Elektronic/Carl Zeiss) to
obtain the number of antigen-positive cells per square
millimeter. Differences in number of neuronal antigen-
containing cells in CLN between treatment groups were
determined by a two-tailed Mann–Whitney test using the
statistical software program SPSS, version 11.0. A signif-
icance level of 0.05 was used.
Results
Presence of neuronal antigens within the CLN of MS
patients
To determine the presence of neuronal antigens in CLN of
MS patients with active disease, cryosections were stained
with antibodies specific for three neuronal antigens: MAP-2,
NSE, and NF-H. Cells containing each of the neuronal
antigens were detectable in CLN from all MS patients,
which were predominantly large cells located in the
medulla of the lymph node with a morphology resembling
macrophages. Neuronal antigen-containing cells were also
found in the paracortex, where dendritic cells and T cells
are located (Fig. 1a–c).
As previously described, neuronal antigen-containing
cells were also present in CLN of control subjects (Fig. 1d–f)
[41, 42]. To investigate whether the presence of neuronal
antigens in CLN of MS patients was the result of neuronal
damage in the CNS or the result of expression by cells in
the CLN, neuronal antigen-containing cells were quantified
and compared with the number of neuronal antigen-
containing cells in CLN of control subjects without
neurological disease. As the numbers of MAP-2-, NSE-,
and NF-H-positive cells in CLN of MS patients and control
subjects were not statistically different (Fig. 1d–f), we
could not definitively conclude that increased neuronal
damage within the CNS resulted in increased neuronal
antigen drainage to CLN. Hence, we performed an
elaborate analysis in a variety of EAE models and in
animal models of non-inflammatory CNS damage (Table 1).
Presence of neuronal antigen-containing cells in CLN
of EAE-affected animals reflects the intensity
of neuronal damage
It has been well established that the rhMOG-induced EAE
model in common marmoset monkeys is characterized by
chronic progressive disease with limited axonal destruction,
whereas the same EAE model in rhesus monkeys follows a
short-lasting acute disease course with extensive axonal
destruction [43]. In CLN of EAE-affected marmoset
monkeys, NSE- and NF-H-containing cells were observed
(Fig. 2a,b). Quantification revealed a higher, but not signifi-
cantly different, number of neuronal antigen-containing cells
in CLN of EAE-affected marmosets as compared to CFA
controls (Fig. 2c,d). In contrast, the CLN of EAE-affected
rhesus monkeys contained significantly more MAP-2 and
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NF-H-containing cells (Fig. 2e,f), than the CLN of CFA
controls (p<0.05; Fig. 2g,h).
The neuronal antigen NF-L was detected in deep CLN
from EAE-affected Biozzi ABH mice with clinical EAE,
but only rarely in superficial CLN (Fig. 2i). This EAE
model is characterized by a first peak of acute disease with
inflammation and axonal injury, followed by one or more
relapses. As an example, Fig. 2k shows the typical
Fig. 1 Neuronal antigens drain to the CLN in MS. CLN of MS
patients contain cells that are positive for the neuronal antigens NSE
(a), MAP-2 (b), and NF-H (c). Scale bars 20 μm; insert 5 μm.
Quantification of the number of MAP-2 (d), NSE (e), and NF-H (f)
positive cells demonstrated a higher, but not significantly different,
number of neuronal antigen-containing cells in CLN of three MS
patients than in CLN of three controls without neurological disease.
Three sections from CLN of each patient were quantified for each
neuronal antigen. Results are shown as box plots with medians, 25th
and 75th percentiles as boxes, tenth and 90th percentiles as whiskers
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relapsing–remitting disease course in this model. CLN
isolated during acute EAE as well as during the first relapse
had significantly more NF-L-containing cells than CFA-
immunized control mice (p<0.05; Fig. 2j). We observed
similar numbers of NF-L-containing cells in the first EAE
episode and the subsequent relapse.
As in CLN of MS patients, neuronal antigen-containing
cells in the CLN of EAE-affected mice and monkeys were
large macrophage-like cells which were located in the
medulla of the lymph node and, although in lower numbers,
in the paracortex.
Drainage of CNS antigens to the CNS-draining lymph
nodes is reflected by the extent and type of CNS damage
To further assess whether the extent and also the type of
CNS insult determines drainage of CNS compounds and to
investigate drainage routes of CNS antigens in mice, we
used different mouse models with non-inflammatory CNS
damage. The MCAO model is characterized by massive
ischemic lesions in the cortex, striatum, and the hippocam-
pus [31]. Superficial as well as deep CLN isolated 24 h
after MCAO contained numerous PLP- and NF-L-contain-
ing cells (Fig. 3b,c). This number was reduced after 72 h
(Fig. 3b,c), indicating rapid and transient drainage follow-
ing CNS damage. In CLN isolated from mice with ECL and
FNA, few PLP- and NF-L-containing cells were observed
in the CLN (Fig. 3b,c), reflecting the mild CNS damage in
these models [44, 45]. The cuprizone model is character-
ized by extensive CNS demyelination induced by cupri-
zone, which selectively kills oligodendrocytes [33]. Little
drainage of the myelin antigen PLP to the superficial CLN
was noticed (Fig. 3a, b). In contrast, the deep CLN of both
SJL/J mice (Fig. 3a,c) as well as C57BL/6 mice (data not
shown) contained significantly higher numbers of PLP-
containing cells (p<0.001). We also detected myelin
antigens in the LLN (Fig. 3a,c), reflecting drainage of
antigens from the spinal cord. Only few NF-L-containing
cells were observed in the CLN of cuprizone-treated mice
(Fig 3b,c), which is in line with the limited neuronal
damage in this model [46].
Neuronal antigen-containing cells have an APC phenotype
Although the majority of neuronal antigen-containing cells
in MS CLN were located in the medulla of the lymph node,
such cells were also found in the paracortex (Fig. 1a–c),
where APC interact with naïve T lymphocytes. We
therefore investigated whether neuronal antigen-containing
cells in MS CLN express APC markers. As expected in a
secondary lymphoid organ, numerous cells in the CLN
expressed major histocompatibility complex (MHC) class II
and CD40 of which only a fraction contained the neuronal
antigen MAP-2. However, almost all (90–100%) MAP-2-
positive cells expressed MHC class II (Fig. 4a) and the
costimulatory molecule CD40 (Fig. 4b). This indicates that
neuronal antigen-containing cells are APC, such as den-
dritic cells or macrophages, which may be involved in the
induction of autoimmunity against neuronal antigens or
conversely in the control of autoreactivity.
T cells in CLN proliferate to MOG peptide, without evident
epitope spreading to NF-L
The localization of neuronal antigens in APC within the
CLN may activate autoreactive T cells. This was tested in
Table 1 Characteristics of MS and the animal models used in this study
Disease Selected characteristics for this study Demyelination Neuronal damage
Human MS Myelin antigens in CLN (neutral lipids, MBP, PLP) [21] Present [2] Present [2]
Marmoset EAE Chronic EAE Present [43] Limited [43]
Myelin antigens in CLN (neutral lipids, MBP, PLP) [21]
Rhesus EAE Acute EAE Dramatic destruction of
myelin [43]
Dramatic destruction
of axons [43]Myelin antigens in CLN (MBP, PLP) [21]
Biozzi ABH EAE Chronic relapsing EAE Little in acute phase,
abundant in relapse [54]
Present in every
phase of disease [54]
C57BL/6 EAE Chronic EAE Present [55] Present [55]




MCAO Ischemic lesions in the cortex, striatum, and hippocampus Massive myelin loss [31] Massive neuronal
loss [31]
ECL Perforant pathway is stereotactically lesioned, leading to
anterograde axonal degeneration within dentate gyrus of the
hippocampus [56]
Limited since the perforant
pathway is not myelinated
Present in
hippocampus [45]
FNA Blood brain barrier remains intact; retraction of the motoneurons
in the brainstem [44]
Limited since the facial
nucleus is not myelinated
Limited [57]
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three independent experiments. Two experiments were
using C57BL/6 mice in which EAE was induced by
injection with MOG35-55 (n=5–10 per experiment). One
additional experiment was using Biozzi ABH mice (n=10)
in which EAE was induced by injection with MOG8-21.
Figure 5 shows a representative experiment, in which we
observed dose-dependent T cell proliferation against the
immunizing peptide MOG35-55 in deep CLN, superficial
CLN as well as in LLN. CLN and LLN from mice
immunized with MOG8-21 demonstrated quantitatively
similar proliferation against MOG8-21 (data not shown).
No proliferation against the irrelevant control antigen
OVA was seen. We did not detect NF-L-specific T cell
proliferation in the two EAE models used for these
experiments.
Differential expression of pro- and anti-inflammatory
molecules by myelin-containing versus neuronal
antigen-containing cells
Myelin-laden myeloid cells in MS brain with foamy
appearance demonstrate a strong anti-inflammatory pheno-
type in situ and in vitro, implying a possible role in the
resolution of local inflammation during MS [38]. To assess
whether this also holds true for myelin antigen-containing
cells and neuronal antigen-containing cells in CLN of MS
patients, we determined the expression of pro- and anti-
inflammatory molecules. The majority of MOG-containing
cells (90–100%) coexpressed the anti-inflammatory mol-
ecules IL-1ra (Fig. 6a) and TGF-β (Fig. 6b), whereas only
a minority of the cells (2–30%) expressed the pro-
Fig. 2 The presence of neuronal antigen-containing cells during EAE
reflects the extent of neuronal damage within the CNS. CLN of EAE-
affected common marmoset monkeys contain NSE (a) and NF-H (b)
positive cells. More NSE (c) and NF-H (d) positive cells were
observed in CLN of five marmosets with EAE as compared to two
CFA-immunized control marmosets, although this difference was not
significant. In CLN of EAE-affected rhesus monkeys, MAP-2 (e) and
NF-H (f) positive cells were found. Quantification of MAP-2 (g) and
NF-H (h) positive cells revealed a significantly higher number of cells
in CLN of five rhesus monkeys with EAE than in CLN of three
collagen-induced arthritis (CIA) control monkeys (*p<0.05). NF-L-
positive cells were present in the deep CLN of EAE Biozzi ABH mice
(i). Deep CLN from three animals with acute disease as well as from
three mice in the first relapse contained significantly more NF-L-
positive cells than CLN from three CFA-immunized control mice (j;
*p<0.05). EAE scores from one representative animal out of three are
shown (k). Three sections from CLN of each monkey and four
sections from CLN of each mouse were quantified for each neuronal
antigen. Results are given as box plots as described in Fig. 1 with
extreme values as filled circles. Scale bars 10 μm
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inflammatory molecule IL-12p40/p70, indicating that
most MOG-containing cells display an anti-inflammatory
phenotype (Table 2). In contrast, none of the MAP-2-
containing cells expressed IL-1ra and TGF-β, while the
majority of the cells (86–100%) expressed IL-12p40/p70
(Fig. 6c) and TNF-α (Fig. 6d), indicating a pro-inflammatory
phenotype (Table 2). These data were paralleled in the CLN
of EAE-affected rhesus monkeys, where 50–95% of the
MOG-containing cells expressed IL-1ra and 13–47%
expressed IL-12p40/p70, whereas 75–94% of the MAP-2-
containing cells expressed IL-12p40/p70 and none expressed
IL-1ra.
Part of MOG-containing cells in CLN of MS patients
express CCR7, whereas MAP-2-containing cells
do not express CCR7
Drainage of CNS antigens to the CLN may either occur as
soluble proteins or within phagocytes [16, 47]. We have
previously shown that myelin antigen-containing cells in
rhesus monkey CLN express the chemokine receptor CCR7
[21], which mediates leukocyte homing to draining lymph
nodes. Similarly, we observed that 20–42% of MOG-
containing cells in human MS CLN expressed CCR7,
whereas none of the MAP-2-containing cells expressed this
Fig. 3 The type and extent of non-inflammatory CNS damage
correlates with the frequencies of CNS antigens in the CNS-draining
lymph nodes. PLP-containing cells in the superficial CLN, deep CLN,
and the spinal cord-draining LLN of cuprizone-treated SJL/J mice.
Scale bars 50 μm (a). Quantification of the number of PLP- and NF-
L-containing cells in the superficial CLN (b) and deep CLN (c).
Tissues were isolated 24 h (n=5) and 72 h (n=5) after MCAO, 7 days
after ECL (n=5), 7 days after FNA (n=3), and after 6 weeks of
cuprizone treatment (Cup; n=3). Cells were quantified in at least two
sections of each tissue. Data represent the mean number of positive
cells±SEM. *p<0.05
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marker (Table 2). These data were paralleled in the CLN of
EAE-affected rhesus monkeys, in which 20–46% of MOG-
containing cells expressed CCR7, and MAP-2-containing
cells did not express CCR7.
To investigate whether CCR7 expression is induced
by the uptake of myelin antigens, we incubated human
monocyte-derived macrophages from healthy donors in
vitro with human myelin and determined CCR7 mRNA
expression and CCR7 surface protein expression. We
observed a time-dependent increase of CCR7 mRNA
expression after myelin ingestion. As compared to
control macrophages, myelin-laden macrophages demon-
strated a 38.4±4.2-fold increase in CCR7 mRNA
expression after 24 h of myelin ingestion, which was
reduced to a 6.3±0.9-fold increase after 7 days of myelin
ingestion. In addition to mRNA, CCR7 surface protein
expression was also increased after myelin ingestion
(data not shown).
Fig. 4 MAP-2-containing cells
in human MS CLN are immu-
nocompetent APC. Immunoflu-
orescent MAP-2 staining in
human MS CLN (red) and
staining for the APC markers
MHC class II (green; a) and
CD40 (green; b). Overlay shows
coexpression of MAP-2 with
MHC class II and CD40, which
was observed in 90% to 100%
of the MAP-2-positive cells.
Nuclei are stained with DAPI
(blue). Stainings were per-
formed on two sections of CLN
from three different MS patients.
Scale bars 5 μm
Fig. 5 Drainage of neuronal antigens to CLN in MOG-peptide-induced
EAE does not elicit a detectable NF-L-specific T cell response.
Stimulation of lymph node cells from deep CLN, superficial CLN,
and LLN from EAE-affected C57BL/6 and Biozzi ABH mice with
rmNF-L, MOG35-55, and ovalbumin demonstrates a dose-dependent
proliferation against the myelin-derived peptide MOG, whereas no
proliferation was observed against NF-L and ovalbumin. Lymph
nodes of five to ten EAE-affected mice were pooled per experiment to
obtain enough cells for restimulation. Results are presented as mean
with the standard deviation of triplicates and are representative for
three independent experiments using two different MOG-peptide-
induced EAE models
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Finally, we assessed whether CCR7 expression affects
the drainage of CNS antigens to CLN. To this end, we
compared the number of CNS antigen-containing cells in
the deep and superficial CLN of EAE-affected CCR7-
deficient and wild-type mice. In our hands, CCR7-deficient
mice developed mild EAE and CLN of these mice were
therefore compared to CLN from wild-type mice with
comparable EAE symptoms. Unexpectedly, the numbers of
both myelin and neuronal antigen-containing cells in CLN
of EAE-affected CCR7-deficient mice were not statistically
different as compared to wild-type mice (Table 3).
Discussion
Interaction between the brain and the secondary lymphoid
organs allows regulation of immune responses in the brain
[48]. This is exemplified by the crucial role of CLN in brain
lesion expansion in cryolesion-enhanced EAE in rats [20]
and by the presence of myelin antigens in APC in CLN of
MS patients and EAE-affected rhesus monkeys and
common marmoset monkeys [21, 22]. The current study
assessed whether neuronal antigens also drain to the CLN
after neuronal damage in the CNS.
Fig. 6 Differential expression
of pro- and anti-inflammatory
molecules by MAP-2- and
MOG-containing cells in human
MS CLN. Immunofluorescent
labeling of MOG (green) and
the anti-inflammatory molecules
IL-1ra (red; a) and TGF-β (red;
b) and immunofluorescent la-
beling of MAP-2 (red) and of
the pro-inflammatory molecules
IL-12p40/p70 (green; c), and
TNF-α (green; d) in human MS
CLN. The overlays show coloc-
alization of MOG and the anti-
inflammatory molecules IL-1ra
and TGF-β, which was ob-
served in 90% to 100% of the
MOG-positive cells, and coloc-
alization of MAP-2 and the
pro-inflammatory molecules IL-
12p40/p70 and TNF-α, which
was observed in 86% to 100%
of the MAP-2-positive cells.
Nuclei are stained with DAPI
(blue). Results are representative
for two sections of CLN from an
MS patient for double stainings
of MOG with TGF-β and TNF-
α and of MAP-2 with TGF-β
and for at least two sections of
CLN from three different MS
patients for double stainings of
MAP-2 with IL-12p40/p70,
TNF-α, and IL-1ra and double
stainings of MOG with IL-1ra
and IL-12p40/p70. Scale bars
5 μm
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MS is both clinically and pathologically a heterogeneous
disease demonstrating various degrees of neuronal damage.
The obtained CLN tissues were therefore from patients at
various disease stages. To further determine drainage in a
more controlled setting with defined disease stages, we
used a variety of EAE models and models of non-
inflammatory CNS insult, representing different degrees of
neuronal damage. We report here that neuronal antigens are
present in CLN of MS patients and of animals after
induction of EAE, MCAO, ECL, and FNA. In rhesus
monkeys and Biozzi ABH mice, animals in which EAE
results in significant neuronal damage within the CNS, the
quantity of neuronal antigen-containing cells in the CLN
reflected the intensity of neuronal damage in the CNS.
Furthermore, qualitative and quantitative drainage of CNS
antigens followed the type and extent of CNS damage in
mice after MCAO, ECL, FNA, and cuprizone treatment.
Interestingly, the frequency of CNS antigens in the CLN
was high 24 h after MCAO and reduced 72 h after MCAO,
indicating that drainage occurs rapidly but transient
following CNS damage. This transient CNS drainage might
also cause the few CNS antigen-containing cells in the
CLN of the ECL and FNA model, which were isolated 7
days after CNS damage induction. These data extend our
previous data and demonstrate that, following CNS dam-
age, both myelin and neuronal antigens drain to CLN.
The presence of neuronal antigen-containing cells in
CLN of control subjects was not unexpected and may be
due to innervation of the CLN [49], expression of neuronal
antigens by the cells themselves [41, 42], or to aging. The
frequency of neuronal antigen-containing cells in CLN
from control subjects seems to differ between species,
which might be due to differential neuronal turnover rates
between species or differential expression levels of neuro-
nal antigens by the cells.
To investigate drainage routes from the brain to the CLN,
we used different non-inflammatory CNS damage models [31,
33, 44–46]. In cuprizone-treated animals, numerous cells
containing myelin antigens were observed in the deep CLN,
whereas such cells were observed only occasionally in the
superficial CLN. We have found the same drainage route in
EAE-affected mice, where we observed high numbers of
neuronal antigen-containing cells in the deep CLN but hardly
in the superficial CLN. These data indicate that CNS antigens
preferentially drain to the deep CLN. In contrast, both the
deep CLN as well as the superficial CLN of MCAO-treated
mice contained numerous CNS antigens. This may be caused
by a different drainage route as the result of the massive CNS
damage or by the fact that this massive CNS damage has
destroyed (part of) the drainage route. Myelin antigens were
also observed in the LLN of cuprizone-treated mice, which
are likely derived from the spinal cord, in which demyelin-
ation also takes place as is the case in MS and EAE. In fact,
whereas CLN are crucial in brain lesion expansion in
cryolesion-induced EAE in rats, they have no effect on lesion
expansion in the lumbar part of the spinal cord [20],
suggesting distinct functional relationships between CNS
compartments and their local draining lymph nodes.
The nature of immune responses against CNS antigens
in the CLN might be dictated by the functional phenotype of
the CNS antigen-containing cells. We therefore determined
the phenotype of myelin and neuronal antigen-containing
cells in human MS CLN. Neuronal antigen-containing cells
in MS CLN expressed the APC markers MHC class II and
CD40, indicating that these cells are equipped for antigen
presentation to T lymphocytes. Furthermore, neuronal
antigen-containing cells were observed in the paracortex
of the lymph node, where APC encounter and activate
naïve T cells. Indeed, T cell responses against neuronal
antigens have been demonstrated in MS patients and EAE-
Table 3 CCR7 deficiency does not affect CNS antigen load in CLN
MOG PLP MAP-2 NF-L
WT 10.3±10.6 0.8±1.1 3.3±4.6 1.5±2.1
CCR7 deficient 29.7±15.7 8.6±6.1 4.7±4.2 4.8±±7.1
Quantification of CNS antigen-containing cells in sections of deep
CLN from four EAE-affected wild-type mice and four EAE-affected
CCR7-deficient mice. Numbers represent mean number of cells per
square millimeter±standard deviation of four sections per animal.
Table 2 Contrasting functional phenotype of MAP-2 versus MOG-containing cells in human MS CLN
Pro-inflammatory molecules Anti-inflammatory molecules Lymph node homing potential
IL-12p40/p70 TNF-α IL-1ra TGF-β CCR7
MAP-2 ++++ ++++ − − −
MOG + +/− ++++ +++ +
Quantification of double labeling of cells in CLN sections of MS patients. − 0%, +/− 1–20%, + 21–40%, ++ 41–60%, +++ 61–80%, ++++ 81–100%
of the cells coexpressing both molecules. Results are representative for two sections of CLN from an MS patient for double stainings of MOG with
TGF-β and TNF-α and of MAP-2 with TGF-β and for at least two sections of CLN from three different MS patients for double stainings of MAP-2
with IL-12p40/p70, TNF-α, IL-1ra, and CCR7 and double stainings of MOG with IL-1ra, IL-12p40/p70, and CCR7.
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affected animals [8–10], and T cell-mediated EAE symp-
toms can be induced by immunization with neuronal
antigens [11, 13, 14]. Despite this, we did not detect T cell
proliferation against NF-L in CLN from EAE mice
immunized with MOG35-55 or MOG8-21. The lack of T cell
proliferation we consistently found might be due to the
absence of intermolecular spreading or to the fact that the
draining antigens may act immunosuppressively on prolif-
eration within the draining lymph nodes.
The current study shows that phagocytes containing the
neuronal antigen MAP-2 in CLN of MS patients and EAE-
affected rhesus monkeys had a pro-inflammatory phenotype.
In contrast, the majority of phagocytes containing the myelin
antigen MOG demonstrated an anti-inflammatory phenotype,
suggesting a relation with the anti-inflammatory myelin-
laden foamy macrophages present within MS lesions [38].
This differential expression of pro- and anti-inflammatory
molecules likely influences the type of immune response
against these antigens. The difference in functional pheno-
type between MAP-2 and MOG-containing cells may be the
consequence of the inflammatory status of the microenvi-
ronment in which the cells have taken up their antigens.
Alternatively, the nature of the phagocytosed antigen may
direct the immunophenotype of the cell into a pro- or anti-
inflammatory mode of action.
As both myelin and neuronal antigens are found in CLN,
the question arises how these antigens reach these lymph
nodes. The two likely mechanisms are either as soluble
antigen or by active transport within phagocytosing cells
[16, 17], such as the anti-inflammatory foamy macrophages
within MS lesions [38]. Since anti-inflammatory macro-
phages express the lymph node homing receptor CCR7
[50], we determined whether a CCR7-dependent mecha-
nism could be involved. This study shows that, similar to
APC in MS brain as well as MOG-containing cells in EAE-
affected rhesus CLN [21, 51], myelin-containing cells in
human MS CLN and in vitro express CCR7, but MAP-2-
containing cells do not. CLN from EAE-affected CCR7-
deficient mice contain slightly more myelin and neuronal
antigens as compared to CLN from EAE-affected wild-type
mice, indicating that CCR7 is not necessarily involved.
This strongly suggests that either other chemokine receptors
are able to guide cell migration to the CLN or that CNS
antigens drain as soluble antigens through CSF to the CLN.
This hypothesis is supported by increased free neuronal
proteins in CSF of MS patients and EAE mice as compared
to healthy controls [52, 53].
In conclusion, we here report that neuronal antigen-
containing cells are present in CLN during MS and in
various animal models for CNS damage. The frequencies of
these cells correlated with the extent of neuronal damage. In
addition, neuronal antigen-containing cells in human MS
CLN are present in functionally different APC subsets as
compared to the majority of myelin antigen-containing
APC. The presence of neuronal antigens in APC with a pro-
inflammatory phenotype and of myelin antigens in APC
with an anti-inflammatory phenotype points at a different
potential to activate functionally distinct T cell subsets.
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